Aldeyra Therapeutics Inc (ALDX)
$3.98
+0.01
(+0.25%)▲
Insights on Aldeyra Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 108.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 309.9%
Performance
- $3.89$4.07$3.98
2.26%
Downside
Day's Volatility :4.42%
Upside
2.21%
- $1.42$11.97$3.98
64.32%
Downside
52 Weeks Volatility :88.14%
Upside
66.75%
Returns
| Period | Aldeyra Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 30.59% | -0.7% | 0.0% |
6 Months | 129.48% | 6.6% | 0.0% |
1 Year | -62.15% | 3.7% | -1.5% |
3 Years | -63.58% | 14.0% | -21.8% |
Highlights
Market Capitalization | 227.9M |
Book Value | $2.02 |
Earnings Per Share (EPS) | -0.64 |
PEG Ratio | 0.0 |
Wall Street Target Price | 9.25 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -16.23% |
Return On Equity TTM | -27.73% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -42.5M |
Diluted Eps TTM | -0.64 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.19 |
EPS Estimate Next Year | -0.41 |
EPS Estimate Current Quarter | -0.14 |
EPS Estimate Next Quarter | -0.14 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 132.41%
Technicals Summary
Sell
Neutral
Buy
Aldeyra Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aldeyra Therapeutics Inc | 42.81% | 129.48% | -62.15% | -63.58% | -48.84% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aldeyra Therapeutics Inc | NA | NA | 0.0 | -0.19 | -0.28 | -0.16 | NA | 2.02 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aldeyra Therapeutics Inc | Buy | $227.9M | -48.84% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Perceptive Advisors LLC
14.59%Knoll Capital Management LP
9.30%Vanguard Group Inc
6.67%BlackRock Inc
5.83%Verition Fund Managegment, LLC
2.25%Kennedy Capital Management Inc
2.17%
Corporate Announcements
Aldeyra Therapeutics Inc Earnings
Aldeyra Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
Organization | Aldeyra Therapeutics Inc |
Employees | 10 |
CEO | Dr. Todd C. Brady M.D., Ph.D. |
Industry | Health Technology |
